Home/Pipeline/NVP-13

NVP-13

Amyotrophic Lateral Sclerosis (ALS)

Pre-clinicalActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Pre-clinical

Status

Active

Company

Velvio, Velvio

About Velvio

Velvio is a preclinical-stage biotech targeting a central biological pathway, TGF-β signaling, with a proprietary LNA-gapmer antisense oligonucleotide platform. Its lead candidate, NVP-13, is designed to downregulate TGFBR2 synthesis to revert inflammation, fibrosis, and restore tissue repair, with first-in-human studies imminent in ALS. The company is pursuing high-unmet-need indications in neurodegeneration, pulmonary fibrosis, and oncology, positioning its platform technology for broad therapeutic application. Led by a small team of experienced founders, Velvio is advancing towards clinical proof-of-concept.

View full company profile

About Velvio

View full company profile

Therapeutic Areas

Neurodegeneration Pulmonary Fibrosis Oncology

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active